Literature DB >> 7089493

Renal function as an indicator of prognosis in malignant essential hypertension.

H Herlitz, T Gudbrandsson, L Hansson.   

Abstract

Renal function was evaluated in a group of 24 patients (21 men and 3 women, mean age 47 years) who had survived the malignant phase of hypertension during the period of 1969-1979. Five had grade III retinopathy (haemorrhages and exudates) and 19 had grade IV changes (papilloedema, FH IV) at diagnosis. Highest recorded blood pressure was 248 +/- 4/152 +/- 3 mmHg (mean +/- S.E.M.). Renal function rapidly deteriorated in 7 cases with progression to terminal uraemia. All patients in this group had a marked elevation in serum creatinine at diagnosis (448 +/- 105 mumol/l) and inadequate blood pressure control. Two of these 7 patients died and 5 underwent renal transplantation. The other 17 patients initially had serum creatinine less than or equal to 250 mumol/l (169 +/- 19 mumol/l-glomerular filtration rate (GFR) 51 +/- 7 ml/min). All except one were reinvestigated after a mean time of 6 years (range 6 months-11 years) with evaluation of blood pressure and determination of GFR by 51Cr-EDTA clearance. At follow-up their blood pressure was fairly well controlled (153 +/- 3/99 +/- 2 mmHg). Their GFR was 62 +/- 6 ml/min. Of the 11 patients in whom two GFR determinations were available (one initially and one at follow-up), six patients showed a marked increase in GFR while 5 patients showed only slight or no improvement in spite of fairly good blood pressure control. In malignant hypertension adequate antihypertensive treatment can lead to a pronounced improvement in GFR unless renal function has deteriorated gravely.

Entities:  

Mesh:

Year:  1982        PMID: 7089493     DOI: 10.3109/00365598209179640

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  2 in total

Review 1.  Hypertensive emergencies and urgencies: definition, recognition, and management.

Authors:  J B Reuler; G J Magarian
Journal:  J Gen Intern Med       Date:  1988 Jan-Feb       Impact factor: 5.128

2.  Clinical evaluation of felodipine in patients with refractory hypertension.

Authors:  H Herlitz; S Björck; G Nyberg; G Granérus; M Aurell
Journal:  Drugs       Date:  1987       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.